Business
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate careTORONTO, Jan. 06...
About this update from Profound Medical Corp
[{"type":"image","alt":"Profound Medical Corp.","displaySize":"","headline":null,"caption":"Profound Medical Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/706e95b61981393723638191940b98c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oleh9hsLn64FmkZjOMsmoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/706e95b61981393723638191940b98c5","width":300,"height":39}},"lazy":false},{"type":"text","content":"Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care","length":138,"tagName":"p"},{"type":"text","content":"TORONTO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the Company’s TULSA-PRO® system. The milestone marks the official launch of TULSA-PRO at one of the world’s most influential centers for prostate cancer innovation and coincides with the opening of Johns Hopkins Medicine’s new interventional MRI (“iMRI”) suite — signaling the continued evolution of MRI from diagnostic imaging-only to a real-time therapeutic platform.","length":766,"tagName":"p"},{"type":"text","content":"The TULSA Procedure™ represents a major advancement in prostate care, and is used by physicians to treat prostate cancer and benign prostatic hyperplasia (“BPH”, also known as an enlarged prostate). Robotically controlled directional ultrasound is delivered from inside the urethra to precisely and gently heat prostate tissue to ‘kill temperature’ (55-57°C) with directional ultrasound, while protecting surrounding nerves and anatomy. Real-time MRI thermography enables continuous visualization and autonomous temperature adjustment throughout the procedure. This level of precision allows physicians to tailor therapy to each patient, resulting in no procedural blood loss, no overnight hospital stay, and a quicker return to everyday life, while minimizing side effects typically associated with surgery or radiation...